Clinical Development

The Company is planning a phase 1/2 clinical trial to test the safety and preliminary anticancer activity of BPS-001 in solid tumors focusing on cancers of the prostate, breast and ovary in the phase 2 portion of the study. Clinical sites will include the Levine Cancer Institute at Carolina Health System (Charlotte, NC), the Winship Cancer Center at Emory University (Atlanta, GA) and the British Columbia Cancer Agency (Vancouver, BC, Canada).